Ingredient Dossier · 5-Brain® Formula · nutropx.com/science

Ginkgo Biloba

The Living Fossil — Earth’s Most Researched Botanical

Ginkgo biloba is a tree species that has survived unchanged for over 270 million years, making it one of the oldest living plant species on Earth. Its standardized leaf extract is among the most extensively studied botanical compounds in all of science — with decades of research investigating its associations with attention, memory-related function, and healthy cerebral circulation.

270 million year old species 50+ years of clinical research 1,000+ published studies Traditional Chinese Medicine Standardized leaf extract

Species age

270M yr

Unchanged since the Permian era

Extract standardized

1960s

EGb 761, Dr. Willmar Schwabe

5-Brain® dose

200 mg

20:1 leaf extract per day

Studied chronic dose

120–240 mg

EGb 761 standardized extract

What is it?

Ginkgo biloba is the last surviving species of the order Ginkgoales — a group of trees that flourished alongside dinosaurs. The species is sometimes called a “living fossil” because fossil specimens from 270 million years ago are nearly indistinguishable from trees alive today. In Traditional Chinese Medicine, ginkgo seeds and leaves have been used for centuries, primarily for respiratory and circulatory applications.

Modern cognitive research centers entirely on standardized leaf extracts, not raw leaf or seeds. The most studied extract in the world is EGb 761 — developed by Dr. Willmar Schwabe GmbH in Germany in the 1960s and standardized to 22–27% ginkgo flavone glycosides and 5–7% terpene lactones (ginkgolides A, B, C and bilobalide), with ginkgolic acids below 5 ppm. EGb 761 is so well-studied that it is licensed as a prescription pharmaceutical in Germany and holds a European Medicines Agency well-established use monograph.

A note on the 5-Brain® Ginkgo extract: 5-Brain® contains a Ginkgo biloba leaf 20:1 extract — meaning 20 kg of leaf was concentrated to produce 1 kg of extract. This concentration ratio is different from the phytochemical standardization (24% flavone glycosides / 6% terpene lactones) used in EGb 761. Until phytochemical equivalence is confirmed with DaVinci Laboratories, the studies below — most of which used EGb 761 — are cited as the best available evidence for standardized ginkgo extract as a class.

Research timeline

~1000 CE

Traditional Chinese Medicine documentation — Ginkgo seeds used in classical TCM preparations for respiratory and circulatory support. The leaf preparations used in modern supplements were developed later.

1960s

EGb 761 standardized extract developed — Dr. Willmar Schwabe GmbH creates the first reproducibly standardized ginkgo leaf extract. This single development makes rigorous clinical research possible and launches the modern era of ginkgo science.

1996–1997

Major RCTs in older adults published — Kanowski et al. (1996, Pharmacopsychiatry) and Le Bars et al. (1997, JAMA) both report significant findings for EGb 761 in older-adult populations experiencing cognitive changes. These landmark papers establish Ginkgo’s clinical profile internationally.

2000–2002

Healthy-adult acute studies — Kennedy, Scholey & Wesnes (2000, 2002) report dose-dependent associations with attention speed in healthy young adults. These studies are among the most-cited acute Ginkgo research in healthy populations.

2002–2005

Mixed chronic results in healthy adults emerge — Solomon et al. (2002, JAMA) finds no memory benefit in healthy adults at 120 mg/day. Elsabagh et al. (2005) finds acute benefit but null results after 6 weeks of daily use, suggesting possible tolerance in healthy populations.

2008–2009

GEM Study — the largest Ginkgo trial ever — DeKosky et al. and Snitz et al. (both JAMA) report from the NIH-funded Ginkgo Evaluation of Memory Study: n=3,069, 6.1 years, EGb 761 240 mg/day. The trial found no significant differences between Ginkgo and placebo on its primary endpoints — an important null finding in older adults. See the study card below for the full result.

2012

Laws meta-analysis — Pooled data from healthy-individual RCTs (n=1,132+) finds near-zero effect sizes for memory, executive function, and attention. Concludes no ascertainable cognitive enhancement benefit in healthy people overall.

How it works — mechanisms of action

EGb 761 contains two primary bioactive fractions — flavone glycosides (kaempferol, quercetin, isorhamnetin) and terpene lactones (ginkgolides A, B, C and bilobalide) — which appear to act through complementary pathways. The ginkgolides and bilobalide are unique to Ginkgo biloba and found in no other plant on Earth.

Ginkgo’s dual mechanism — cerebrovascular support and antioxidant defense

Ginkgo’s two complementary mechanisms operate at the vascular and antioxidant levels. The terpene lactones (ginkgolides + bilobalide) act through PAF antagonism and cerebrovascular effects; the flavone glycosides act as antioxidants. Diagram is schematic.

Ginkgo bioactives

Reactive oxygen species

Cerebral blood vessel

Professor 5-Brain explains

Ginkgo’s story is really about getting blood and nutrients to the brain efficiently. The terpene lactones help keep blood flowing smoothly by reducing platelet clumping, while the flavonoids act as antioxidants protecting the vessels themselves. Think of it like keeping the brain’s supply roads clear and in good condition. That’s why the research on attention tends to be more consistent than memory — better flow means faster signal delivery, which shows up most clearly in reaction time and focus tasks.

Cerebral circulation support

Ginkgolides and bilobalide are studied for vasodilatory effects and modulation of cerebral blood flow — potentially supporting the delivery of oxygen and glucose to brain tissue, which may underlie acute attention effects.

Antioxidant & free-radical scavenging

The flavone glycoside fraction is studied for its antioxidant activity — potentially protecting neuronal membranes and blood vessel walls from oxidative stress, a key mechanism in cerebrovascular health.

Platelet-activating factor (PAF) antagonism

Ginkgolide B is a studied PAF antagonist — PAF promotes platelet aggregation and inflammation. This is both a potential circulatory benefit and the basis for the bleeding interaction concern with anticoagulant medications.

Mitochondrial protection

Bilobalide has been studied for mitochondrial protective effects under conditions of metabolic stress — potentially supporting neuronal energy supply and resilience to ischemic challenge.

Neurotransmitter modulation

EGb 761 has been studied for associations with monoaminergic neurotransmission — including modulation of dopamine and serotonin pathways — which may contribute to the mood and attention findings in some trials.

HPA-axis & stress modulation

Some research suggests Ginkgo may influence the stress-cortisol response axis, with potential implications for maintaining cognitive function during periods of heightened stress.

5-Brain® system mapping

Based on the available human clinical evidence, Ginkgo biloba’s most defensible associations in healthy adults are with attention-related and circulation-support mechanisms.

Focus & Attention

Primary studied domain in healthy adults. Kennedy 2000 reported dose-dependent associations with attention speed in a single-dose trial. Most consistent single finding across healthy-adult acute trials.

Brain Energy & Longevity

Studied for cerebral circulation support, mitochondrial protection, and antioxidant activity — mechanisms associated with long-term neuronal energy supply and resilience.

Memory & Learning

Mixed evidence in healthy adults. Modest delayed-recall benefit in older adults (Mix & Crews 2002). General healthy-adult memory meta-analysis (Laws 2012) was null overall.

Mood & Stress Resilience

Indirect associations via neurotransmitter modulation. Not a primary studied domain for healthy adults in published clinical trials.

Neural Communication

Potential indirect association via cerebral blood flow mechanisms. Not a primary mechanism supported by direct human trial evidence.

Human clinical evidence

The studies below include both positive findings and significant null results. Understanding the full picture — including where the evidence does not support claims — is essential for honest, compliant communication about this ingredient.

Acute RCT · Healthy adults

Kennedy, Scholey & Wesnes (2000) — Psychopharmacology

n=20 healthy young adults · Single doses: 120, 240, 360 mg · Standardized extract GK501

In this acute trial, researchers reported a sustained, dose-dependent association with speed of attention across the day, with 240 mg and 360 mg doses showing the clearest results. Participants were healthy young adults. This is one of the most-cited acute Ginkgo studies in healthy populations.

PMID 11026748 Extract: GK501 (Pharmaton) — not EGb 761; not 5-Brain’s extract

Key takeawayHealthy elderly volunteers at 120 mg/day EGb 761 reported associations with working memory and processing speed. Used EGb 761 specifically (the gold-standard branded extract) — not confirmed equivalent to 5-Brain®’s 20:1 extract. Population: older adults.

Double-blind RCT · Cognitively intact older adults

Mix & Crews (2002) — Human Psychopharmacology

n=262, community-dwelling adults ≥60, cognitively intact · EGb 761 180 mg/day · 6 weeks

Researchers reported statistically significant associations with delayed free recall and recognition memory for auditory-verbal material in the EGb 761 group vs placebo. A significantly greater proportion of participants in the Ginkgo group self-rated their memory as improved. Effects were described as modest and limited to specific memory measures — not global cognition. Population: cognitively intact older adults.

PMID 12404671 Extract: EGb 761 (gold standard)

Key takeawayNull finding in healthy young adults at acute single doses. Suggests Ginkgo is not an acute-effect ingredient in young adults at typical doses. Underscores the chronic-dosing pattern.

Double-blind RCTNull — chronic use in healthy adults

Elsabagh et al. (2005) — Psychopharmacology

n=52 (acute) / n=40 (chronic) · Healthy university students · 120 mg/day · 6 weeks chronic

In the acute arm, researchers reported associations with sustained attention and pattern-recognition memory at 120 mg. However, after 6 weeks of daily use, no significant associations with any cognitive or mood measure were observed — suggesting possible tolerance to the acute effects in healthy young adults. An important finding for honest communication about daily-use expectations.

PMID 15739076 Acute positive; chronic null

Key takeawayGEM Study — the largest healthy-aging Ginkgo RCT. 6 years, 3,069 elderly, EGb 761 240 mg/day. Found no significant cognitive associations. The most important null finding in the modern Ginkgo literature. Healthy-adult dementia prevention claims are not supported by this trial.

RCT · JAMANull — healthy older adults

Solomon et al. (2002) — JAMA

n=230, community-dwelling adults >60 · 120 mg/day · 6 weeks

No significant differences between Ginkgo and placebo on any objective neuropsychological measure — learning, memory, attention, concentration, or naming — nor on self-report or companion ratings. Authors concluded Ginkgo provides no measurable memory or cognitive benefit in adults with healthy cognitive function.

PMID 12186600

Key takeawayHealthy older adults at EGb 761 180 mg/day reported associations with memory measures. Different population than 5-Brain®’s target market; used branded EGb 761.

Null — dementia prevention · n=3,069 · NIH-funded

DeKosky et al. (2008) — JAMA · GEM Study

n=3,069 · Ages ≥75 · EGb 761 240 mg/day · Median 6.1-year follow-up

The largest Ginkgo trial ever conducted. EGb 761 at 240 mg/day for over 6 years did not reduce the incidence of dementia or Alzheimer’s disease compared to placebo. We include this null result for full scientific transparency about Ginkgo’s evidence base in age-related cognitive decline research.

PMID 19017911 Extract: EGb 761 · Disease-prevention research context

Key takeawayNull finding in healthy older adults at EGb 761 240 mg/day. Yet another negative trial in the modern literature. Supports a balanced view: Ginkgo effects in healthy older adults are not reliable across trials.

Meta-AnalysisNull — healthy people

Laws, Sweetnam & Kondel (2012) — Human Psychopharmacology

Pooled n=1,132 (memory) · 534 (executive function) · 910 (attention) · Healthy individuals

Effect sizes were non-significant and near zero across all domains: memory d=−0.04, executive function d=−0.05, attention d=−0.08. Effects were unrelated to dose, duration, age, or sample size. Authors concluded Ginkgo had no ascertainable positive cognitive enhancement effects in healthy individuals.

PMID 23001963

Key takeawayHealthy adults at EGb 761 240 mg/day reported associations with attention and information processing measures. Methodologically rigorous; used EGb 761.

Double-blind RCT · Dementia population

Kanowski et al. (1996) — Pharmacopsychiatry

n=156 · Mild-to-moderate dementia · EGb 761 240 mg/day · 24 weeks

Statistically significant differences vs placebo on the SKT cognitive test, CGI clinical global impression, and behavioral measures. A landmark study establishing EGb 761’s clinical profile in a research population with diagnosed mild-to-moderate dementia. Population: adults with diagnosed mild-to-moderate dementia — not healthy adults.

PMID 8724753 Diagnosed dementia population · Research context

Key takeawayFoundational older RCT in cognitive complaints population. Reported associations with memory measures at 240 mg/day. Population is cognitively impaired (clinical context); not direct healthy-adult evidence.

What the research actually says

Honest evidence summary

Ginkgo biloba has one of the most extensive research histories of any botanical — and one of the most nuanced evidence profiles. The honest framing requires acknowledging both the real findings and the major null trials in the same breath.

What studies consistently support

Acute, single-dose studies in healthy young adults have reported associations with attention speed and processing efficiency at 240+ mg of EGb 761.
The two bioactive fractions (terpene lactones, flavone glycosides) have characterized mechanisms: cerebrovascular support via PAF antagonism, and antioxidant activity respectively.
Ginkgo has 50+ years of clinical safety data — one of the most thoroughly characterized botanicals.
EGb 761 (the 24%/6% flavonoid/terpene standardized extract) has the strongest evidence base of any specific Ginkgo preparation.

What remains uncertain

Whether 5-Brain®’s 20:1 extract is equivalent to EGb 761. Most positive cognitive research used EGb 761 specifically; 20:1 extracts are not confirmed equivalent.
Whether chronic daily use in healthy adults produces cognitive effects. The Laws 2012 meta-analysis found near-zero effect sizes across memory, attention, and executive function in healthy people.
Whether acute attention benefits persist with chronic use. Elsabagh 2005 found the acute effect disappeared after 6 weeks of daily use — possible tolerance development.
Whether healthy-adult effects exist at all at the 5-Brain® dose. The GEM Study (n=3,069 over 6 years at 240 mg/day EGb 761) found no significant cognitive effects in healthy older adults.

What to realistically expect

Ginkgo’s role in 5-Brain® is positioned around the cerebrovascular and antioxidant mechanisms, not as a primary cognitive enhancer.
The 50+ year safety profile and well-characterized chemistry are real value — even where chronic-use cognitive effects are uncertain.
Ginkgo contributes a circulatory dimension to the multi-ingredient formula that no other 5-Brain® ingredient directly addresses.
Do not expect Ginkgo to function like an acute focus aid — treat it as background circulatory support, not as the formula’s active cognitive driver.

Professor 5-Brain — the honest take

Ginkgo is the most polarizing ingredient in 5-Brain® from an evidence standpoint — it has a massive research literature with both impressive findings and major null trials in the same population. Other brands ignore the null trials; we don’t. We include Ginkgo because its cerebrovascular mechanism is a distinct biochemical angle that complements the other five ingredients, and because the 50-year safety profile means we know exactly what we’re working with. We’re not telling you Ginkgo will make you smarter at our dose. We’re telling you it’s contributing to a multi-mechanism formula in a defensible, characterized way.

Why we selected this form

Formulation rationale

The broadest research history of any botanical in the formula. Ginkgo has been studied in clinical trials for over 50 years. The depth of the scientific record — even where findings are mixed — provides a level of safety understanding and mechanistic characterization that newer ingredients simply cannot match.

Circulatory support mechanism complements other ingredients. Ginkgo’s studied role in supporting healthy cerebral circulation provides a mechanistic dimension — getting nutrients and other active compounds to brain tissue efficiently — that no other ingredient in the 5-Brain® formula directly addresses.

Standardization note. The strongest research evidence for Ginkgo cognitive effects is tied to EGb 761 — the defined 24%/6% standardized extract. 5-Brain® uses a 20:1 concentration ratio extract. We are working to confirm whether this extract meets the phytochemical standardization of EGb 761 with our manufacturing partner, DaVinci Laboratories. We will update this page when confirmed.

Synergy within the 5-Brain® formula

Ginkgo + Bacopa

Ginkgo is studied for cerebral circulation support; Bacopa is studied for memory-related signaling pathways. These represent complementary mechanistic dimensions within the 5-Brain® formula.

Circulation + Memory signaling

Ginkgo + Sharp-PS® Green

Ginkgo is studied for cerebrovascular mechanisms; phosphatidylserine is studied for the structural integrity of neuronal membranes. These represent complementary mechanistic dimensions — vascular and structural — within the 5-Brain® formula.

Vascular + Structural

Ginkgo + Meriva® Curcumin

Both ingredients have studied associations with antioxidant and healthy inflammatory-response pathways in the brain. Potentially complementary oxidative defense mechanisms supporting long-term brain health.

Dual antioxidant support

Ginkgo + Chocamine®

Chocamine® (theobromine) is studied for associations with gentle vasodilation and immediate focus. Ginkgo is studied for cerebral circulation mechanisms. Both ingredients have studied associations with vascular pathways relevant to brain function.

Complementary vasodilation

Dosage & timing

5-Brain® dose

200 mg

per day · 20:1 leaf extract · with daily serving

Studied chronic doses in clinical trials ranged from 120–240 mg/day of standardized EGb 761 extract — 5-Brain’s 200 mg falls within this range by quantity

Acute attention effects in research studies appeared within hours of single doses (Kennedy 2000) — suggesting some effects may be relatively near-term

Take consistently with the rest of the 5-Brain® formula — Ginkgo’s circulatory support mechanisms are complementary to the other ingredients in the stack

Discontinue 2 weeks before any planned surgery — Ginkgo’s PAF-antagonist mechanism may affect platelet function. Consult your healthcare provider.

Safety & tolerability

Important drug interaction: Ginkgo’s ginkgolides are platelet-activating factor (PAF) antagonists. There are documented case reports of serious bleeding events — including spontaneous intracranial hematoma — particularly when combined with anticoagulants (warfarin), antiplatelets (aspirin, clopidogrel), or NSAIDs. A large Veterans Administration database analysis found combining Ginkgo with warfarin significantly increased bleeding risk (HR 1.38, 95% CI 1.20–1.58). Do not take 5-Brain® if you are on anticoagulant or antiplatelet therapy without first consulting your healthcare provider.

General tolerability

Well tolerated at 120–240 mg/day in clinical trials across multiple populations
Decades of widespread use with an established safety profile at standard doses
EMA well-established use monograph supports safety at standard extract doses
Most common mild effects: headache, GI upset, dizziness — typically transient

Important cautions

Do not combine with warfarin, clopidogrel, aspirin, or NSAIDs without physician guidance
Discontinue at least 2 weeks before surgery — platelet function may be affected
Not recommended in pregnancy — consult your healthcare provider
High-dose rodent studies found thyroid and liver tumors (NTP 2013); relevance at human supplement doses is not established — IARC Group 2B classification

Frequently asked questions

Does Ginkgo actually support memory function?

The honest answer is: it depends on the population and how you measure it. In healthy adults, the most comprehensive meta-analysis (Laws 2012, pooled n=1,100+) found near-zero effect sizes for memory. In older adults with some age-related cognitive change, there is more consistent evidence of modest memory-related associations (Mix & Crews 2002). The published research most consistently associates Ginkgo with attention-related outcomes in acute healthy-adult trials, and with healthy cerebral circulation at the mechanistic level.

What is EGb 761 and is it in 5-Brain®?

EGb 761 is the specific standardized Ginkgo extract developed by Dr. Willmar Schwabe GmbH in Germany — standardized to 24% flavone glycosides and 6% terpene lactones. It is the extract used in the majority of positive clinical trials and is licensed as a pharmaceutical in Europe. 5-Brain® uses a 20:1 concentration ratio extract. We are working to confirm phytochemical equivalence with our manufacturing partner, DaVinci Laboratories, and will update this page when confirmed.

Can I take Ginkgo with other medications?

Ginkgo has a documented interaction with anticoagulant and antiplatelet medications (warfarin, clopidogrel, aspirin) and NSAIDs due to its platelet-activating factor antagonism. If you take any of these, consult your healthcare provider before taking 5-Brain®. Discontinue use at least 2 weeks before any planned surgical procedure.

Why is Ginkgo included in 5-Brain® if some studies were null?

The 5-Brain® formula is designed as a multi-ingredient system where each ingredient contributes to a different mechanism. Ginkgo’s primary contribution is cerebral circulation support and antioxidant activity — mechanisms that complement other ingredients in the stack rather than duplicate them. No single ingredient is expected to deliver all cognitive benefits alone; the formula logic is about complementary support across multiple pathways.

How long has Ginkgo biloba been studied scientifically?

The standardized extract EGb 761 was developed in the 1960s, meaning rigorous clinical research has been ongoing for over 50 years — longer than almost any other botanical nootropic. The species itself is a “living fossil” that has survived unchanged for 270 million years, making it one of the longest-documented plants in both traditional medicine and modern science.

← All Nutropx ingredient research

References
Kennedy DO, Scholey AB, Wesnes KA (2000) Psychopharmacology 151:416–23 · PMID 11026748 · Kennedy DO, Scholey AB, Wesnes KA (2002) Physiol Behav 75:739–51 · PMID 12020739 · Mix JA, Crews WD Jr (2002) Hum Psychopharmacol 17:267–77 · PMID 12404671 · Solomon PR et al. (2002) JAMA 288:835–40 · PMID 12186600 · Elsabagh S et al. (2005) Psychopharmacology 179:437–46 · PMID 15739076 · DeKosky ST et al. (2008) JAMA 300:2253–62 · PMID 19017911 · Snitz BE et al. (2009) JAMA 302:2663–70 · PMID 20040554 · Laws KR, Sweetnam H, Kondel TK (2012) Hum Psychopharmacol 27:527–33 · PMID 23001963 · Kanowski S et al. (1996) Pharmacopsychiatry 29:47–56 · PMID 8724753

This page is for educational and informational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. If you are taking anticoagulant, antiplatelet, or blood-thinning medications, consult your healthcare provider before use. Discontinue use at least 2 weeks before surgery. Consult your healthcare provider before beginning any supplement regimen, particularly if you are pregnant, nursing, taking medications, or have a medical condition.